scholarly journals Outcomes of adjunctive radiation therapy for the treatment of mast cell tumors in dogs and assessment of toxicity: A multicenter observational study of 300 dogs

2021 ◽  
Author(s):  
Sarah L. Mason ◽  
Charles Pittaway ◽  
Begona Pons Gil ◽  
Onne‐Marju Russak ◽  
Katie Westlake ◽  
...  
Keyword(s):  
Mast Cell ◽  
Radiation Therapy ◽  
Observational Study ◽  
Multicenter Observational Study ◽  
Mast Cell Tumors

scholarly journals A Prospective Study of Radiation Therapy for the Treatment of Grade 2 Mast Cell Tumors in 32 Dogs

1996 ◽  
Vol 10 (6) ◽  
pp. 376-378 ◽  
Author(s):  
Renee Al-Sarraf ◽  
G. Neal Mauldin ◽  
Amiya K. Patnaik ◽  
Karri A. Meleo
Keyword(s):  
Mast Cell ◽  
Radiation Therapy ◽  
Prospective Study ◽  
Mast Cell Tumors ◽  
A Prospective Study

RADIATION THERAPY FOR INCOMPLETELY RESECTED CANINE MAST CELL TUMORS

1998 ◽  
Vol 39 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Tracy Ladue ◽  
G. Sylvester Price ◽  
Richard Dodge ◽  
Rodney L. Page ◽  
Donald E. Thrall
Keyword(s):  
Mast Cell ◽  
Radiation Therapy ◽  
Mast Cell Tumors

Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993)

1997 ◽  
Vol 33 (4) ◽  
pp. 320-324 ◽  
Author(s):  
AE Frimberger ◽  
AS Moore ◽  
SM LaRue ◽  
JM Gliatto ◽  
AE Bengtson
Keyword(s):  
Mast Cell ◽  
Radiation Therapy ◽  
Total Dose ◽  
Local Control ◽  
Linear Accelerator ◽  
Surgical Scar ◽  
Mast Cell Tumors ◽  
Cutaneous Mast Cell ◽  
One Year ◽  
Surgical Excisions

Thirty-seven dogs with moderately differentiated, cutaneous mast cell tumors had incomplete surgical excisions as determined by histopathology, but no gross evidence of tumor. All dogs were irradiated to a total dose of between 46.2 and 48.0 Gy using either an orthovoltage source (n = 20) or a linear accelerator (megavoltage) (n = 17). Radiation was delivered to an area bordered by margins of 3 cm or greater around the surgical scar. The mast cell tumors had not recurred in 97% of dogs by one year after radiation therapy and had not recurred in 93% of dogs by three years after radiation. Both orthovoltage and megavoltage radiation provide excellent local control of moderately differentiated mast cell tumors in dogs.

Adjuvant CCNU (Lomustine) and Prednisone Chemotherapy for Dogs With Incompletely Excised Grade 2 Mast Cell Tumors

2009 ◽  
Vol 45 (1) ◽  
pp. 14-18 ◽  
Author(s):  
Kenji Hosoya ◽  
William C. Kisseberth ◽  
Francisco J. Alvarez ◽  
Ana Lara-Garcia ◽  
Gillian Beamer ◽  
...  
Keyword(s):  
Mast Cell ◽  
Radiation Therapy ◽  
Local Recurrence ◽  
Medical Records ◽  
Local Recurrence Rate ◽  
Distant Metastases ◽  
Surgical Excision ◽  
Mast Cell Tumors ◽  
Fatal Liver Failure ◽  
Metastasis Rate

The use of adjuvant 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; lomustine) to treat incompletely excised canine mast cell tumors (MCTs) has not been evaluated. Medical records of 12 dogs with grade 2 MCT treated with incomplete surgical excision and adjuvant CCNU and prednisone chemotherapy were reviewed. Local recurrence rate, metastasis rate, and survival time were evaluated. None of the dogs developed local recurrence or regional/ distant metastases. Two dogs developed fatal liver failure. The 1- and 2-year progression-free rates of surviving dogs were 100% and 77%, respectively. Postoperative adjuvant CCNU appears to be a useful alternative to radiation therapy for incompletely excised canine cutaneous MCTs.

A multicenter observational study of cs-131 seeds embedded in a collagen carrier tile in intracranial brain neoplasms: Trial in progress.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS2073-TPS2073
Author(s):  
K. Stuart Lee ◽  
Matthew Peach ◽  
Clark C Chen ◽  
Kathryn Dusenbery ◽  
Clara Ferreira ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Radiation Therapy ◽  
Adverse Events ◽  
Observational Study ◽  
Clinical Outcomes ◽  
Real World ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Multicenter Observational Study ◽  
Patient Reported

TPS2073 Background: Brachytherapy is an efficacious means for radiation delivery in the treatment of a spectrum of central nervous system tumors. Traditional brachytherapy methods have been limited by uneven dose distribution, complicated workflow, extended procedural times, the cost of dedicated equipment, and frequent adverse events. To address these issues, a permanently implanted device with Cs-131 radiation seeds embedded in a bioresorbable collagen carrier tile (GammaTile [GT], GT Medical Technologies, Tempe, AZ USA) was developed. Described as surgically targeted radiation therapy (STaRT) to distinguish it from external beam radiation therapy, the device is FDA-cleared for use in newly diagnosed malignant intracranial neoplasms and recurrent intracranial tumors, and has demonstrated excellent safety and local control outcomes in early commercial use. Methods: The overarching primary objectives of this multicenter, prospective, observational (phase IV) registry study are to evaluate “real-world” clinical outcomes and patient reported outcomes that measure the safety and efficacy of STaRT using the GT device. The registry is planned for 600 prospectively enrolled subjects at up to 50 enrolling sites. All adult patients undergoing surgical resection of brain tumors of any pathology with intra-operative GT placement are eligible for enrollment, upon consent. Information on patient demographics, tumor pathology, overall survival, adverse events related to radiation or surgery, and quality of life (FACT-Br and LASA) will be collected. Serial MRIs will be collected, and timing of surgical bed recurrence and/or distant recurrence will be collected. Data will be collected at 1-, 3-, 6-, 9-, 12-, 18-, and 24-months, then every 6 months through 5 years. Results will be used to benchmark clinical outcomes of GT therapy, allow for comparisons to other existing treatments, and facilitate the design of future clinical trials. Enrollment opened on November 15, 2020, and seven subjects have been enrolled to date at three centers. This study will be the first observational study of resection plus STaRT, delivered by Cs-131 sources in permanently implanted bioresorbable collagen tile carriers, and will allow for evaluation of this treatment approach in a real world setting, as well as provide an information platform for cross-comparison of results obtained from ongoing GT clinical trials. Clinical trial information: NCT04427384.

ENDOSCOPIC PAPILLECTOMY IN A LARGE MULTICENTER OBSERVATIONAL STUDY: STILL WAY FOR IMPROVEMENT

2020 ◽  
Author(s):  
H Gondran ◽  
E Coron ◽  
N Musquer ◽  
EPC Robles ◽  
P Dreprez ◽  
...  
Keyword(s):  
Observational Study ◽  
Multicenter Observational Study ◽  
Endoscopic Papillectomy
Sign in / Sign up

Export Citation Format

Share Document